1227573-02-5

Basic information

• Product Name: 3-bromo-5-fluoroisonicotinaldehyde
• Synonyms: 3-bromo-5-fluoroisonicotinaldehyde;4-Pyridinecarboxaldehyde, 3-broMo-5-fluoro-;3-Bromo-5-fluoropyridine-4-carboxaldehyde;3-Bromo-5-fluoro-pyridine-4-carbaldehyde
• CAS NO: 1227573-02-5
• Molecular Formula: C₆H₃BrFNO
• Molecular Weight: 203.9965232
• Mol File: 1227573-02-5.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 227.5±35.0 °C(Predicted)
• Appearance: /
• Density: 1.778±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -1.54±0.28(Predicted)
• CAS DataBase Reference: 3-bromo-5-fluoroisonicotinaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 3-bromo-5-fluoroisonicotinaldehyde(1227573-02-5)
• EPA Substance Registry System: 3-bromo-5-fluoroisonicotinaldehyde(1227573-02-5)

Safety Data

• Hazardous Substances Data: 1227573-02-5(Hazardous Substances Data)

Usage

General Description

3-bromo-5-fluoroisonicotinaldehyde is a chemical compound with the molecular formula C7H4BrFNO. It is an aldehyde derivative of isonicotinic acid, containing a bromine atom at the 3-position and a fluorine atom at the 5-position. 3-bromo-5-fluoroisonicotinaldehyde has potential applications in pharmaceutical and agrochemical industries due to its versatile reactivity and structural features. It can be used as a building block for the synthesis of various heterocyclic compounds and organic intermediates. 3-bromo-5-fluoroisonicotinaldehyde is also employed in the development of new drugs and crop protection chemicals, making it a valuable component in chemical research and industry.

Upstream product

• 407-20-5 3-bromo-5-fluoropyridine 
• 68-12-2 N,N-dimethyl-formamide 
• 109-94-4 formic acid ethyl ester 

Downstream Products

• 1308669-84-2 2-chloro-4-(5-fluoro-4-formyl-pyridin-3-yl)-benzonitrile 
• 1308668-85-0 2-chloro-4-(5-fluoro-4-hydroxymethyl-pyridin-3-yl)-benzonitrile 
• 1032943-43-3 4-bromo-1H-pyrazolo[3,4-c]pyridine 

Relevant articles and documents

THERAPEUTIC INHIBITORY COMPOUNDS

Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.

6,7-HETEROCYCLIC FUSED 5H-PYRROLO[1,2-C]IMIDAZOLE DERIVATIVES AND THEIR USE AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) AND/OR TRYPTOPHAN 2,3-DIOXYGENASE (TD02) MODULATORS

This invention relates to novel compounds of formula (I) wherein 'A' is a 5 or 6 membered heteroaryl group, unsubstituted or substituted with 1, 2 or 3 groups as defined in claim 1; X is a bond or -(CRA1RB1)n-; Y is selected from: a bond, -(CRDRE)m-, -O-, -NRF, -S-, -C(O)-, -C(NRF) -, -C(ORF)Rc-, -C(NRFRG)RC-, -C(O)NRF, -NRFC(O)-, -NRFC(O)NRG-, - NRFSO2NRG-, -SO2-, -SO2NRF-, -NRFSO2-, -OC(O)- and -C(O)O-; Z is a bond or -(CRA2RB2)k-; wherein m, n and k are each independently selected from 1, 2, 3 and 4; R1 is H or a 3 to 16 membered fully saturated, partially unsaturated or aromatic mono-, di- or tri-cyclic moiety, which optionally may include 1, 2 or 3 heteroatoms selected from O, N and S, and which is unsubstituted or substituted with 1 to 5 substituents as defined in claim 1; R2 is selected from: H, halo, C1-4alkyl, C1-4 haloalkyl, -ORA4 and C1-4alkyl substituted with -ORA4; and R3 and R4 are each independently selected from: H, halo, C1-4alkyl, C1-4haloalkyl, C3-6cycloalkyl, -ORA4, -NRA5RB4, -CN, -SRAS and C1-4alkyl substituted with -ORA5; and pharmaceutical compositions comprising the novel compounds. More specifically, the invention relates to compounds useful as indoleamine 2,3-dioxygenase (IDO) and/or tryptophan 2,3- dioxygenase (TD02) modulators (e.g. IDOl, and ID02 and/or TD02 inhibitors).

BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYMTHASE INHIBITORS

The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical comp